Search results
Results from the WOW.Com Content Network
Dipeptidyl peptidase 4 (DPP-4) inhibitors are a class of medicine that lower high blood glucose levels and may be used in the treatment of type 2 diabetes. DPP-4 inhibitors slow the inactivation and degradation of GLP-1, a hormone involved in glucose removal from the gut. DPP-4 inhibitors improve blood glucose control and reduce both fasting ...
Januvia is classified as a dipeptidyl peptidase-4 (DPP-4) inhibitor. It lowers blood sugar levels by increasing the release of insulin from your pancreas in response to a meal. Related questions. How and where do you inject liraglutide? Can liraglutide be used for weight loss? What is the difference between Soliqua and Xultophy?
Zituvio is a DPP-4 inhibitor (dipeptidyl peptidase-4 inibitor). Zituvio received FDA-approval on October 18, 2023, along with diet and exercise to improve glycemic control in adults who have type 2 diabetes mellitus.
In patients with metformin contraindications or intolerance (e.g., risk of lactic acidosis, GI intolerance) or in selected other patients, some experts suggest that initial therapy with a drug from another class of antidiabetic agents (e.g., a glucagon-like peptide-1 [GLP-1] receptor agonist, sodium-glucose cotransporter 2 [SGLT2] inhibitor ...
An association between dipeptidyl peptidase-4 (DPP-4) inhibitor treatment and heart failure has been observed in cardiovascular outcomes trials for two other members of the DPP-4 inhibitor class. These trials evaluated patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease.
Common Januvia side effects may include: low blood sugar; headache; or. runny or stuffy nose, sore throat. This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. Januvia side effects (more detail)
Type-2 diabetes is a disease in which the pancreas does not make enough insulin to control the level of glucose (sugar) in the blood or when the body is unable to use insulin effectively. The active substance in Galvus, vildagliptin, is a dipeptidyl-peptidase-4 (DPP-4) inhibitor.
Common side effects of saxagliptin may include: painful urination; headache; runny or stuffy nose, sore throat, cough; or. swelling in your hands or feet. This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Dipeptidyl peptidase-4 inhibitors: Postmarketing reports: Bullous pemphigoid ; Postmarketing reports of bullous pemphigoid requiring hospitalization have been reported with dipeptidyl peptidase-4 (DPP-4) inhibitors use. These case typically recovered with topical or systemic immunosuppressive treatment and discontinuation of DPP-4 inhibitor.
Normally, incretin hormones are rapidly deactivated by an enzyme called dipeptidyl peptidase 4 (DPP-4). However, Januvia is in a class of drugs known as dipeptidyl peptidase 4 (DPP-4) inhibitors, which work by blocking the deactivation of incretin hormones. By increasing and prolonging active incretin levels, Januvia increases insulin release ...